Paradigm4’s Marilyn Matz reflects on the understanding complex biological phenomena has required concurrent advances in experimental methods and computing power.
Paradigm4’s Marilyn Matz reflects on the understanding complex biological phenomena has required concurrent advances in experimental methods and computing power.
Over the past 5 decades or so, the growing understanding that RNA can influence protein function through routes other than direct translation has opened the prospect of discovering small molecules for tackling diseases in novel ways.
Marilyn Matz, CEO of Paradigm4, and Zachary Pitluk, Vice President of Life Sciences at Paradigm4, explain why scalable data science platforms are key to supporting integrated analysis of single-cell genomic data sets.
The past few years have seen several flashy demonstrations of how artificial intelligence (AI) algorithms may transform biomedical research, particularly with respect to drug discovery.